- Home
- EXK vs GERN Comparison
EXK vs GERN Comparison
Compare EXK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXK
- GERN
- Stock Information
- Founded
- EXK 1981
- GERN 1990
- Country
- EXK Canada
- GERN United States
- Employees
- EXK N/A
- GERN N/A
- Industry
- EXK Precious Metals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- EXK Basic Materials
- GERN Health Care
- Exchange
- EXK Nasdaq
- GERN Nasdaq
- Market Cap
- EXK 949.5M
- GERN 853.5M
- IPO Year
- EXK N/A
- GERN 1996
- Fundamental
- Price
- EXK $4.00
- GERN $1.47
- Analyst Decision
- EXK Strong Buy
- GERN Buy
- Analyst Count
- EXK 3
- GERN 9
- Target Price
- EXK $6.83
- GERN $5.13
- AVG Volume (30 Days)
- EXK 13.5M
- GERN 13.0M
- Earning Date
- EXK 05-13-2025
- GERN 05-07-2025
- Dividend Yield
- EXK N/A
- GERN N/A
- EPS Growth
- EXK N/A
- GERN N/A
- EPS
- EXK N/A
- GERN N/A
- Revenue
- EXK $217,412,000.00
- GERN $116,293,000.00
- Revenue This Year
- EXK $99.18
- GERN $160.12
- Revenue Next Year
- EXK $49.21
- GERN $55.01
- P/E Ratio
- EXK N/A
- GERN N/A
- Revenue Growth
- EXK 1.72
- GERN 22264.04
- 52 Week Low
- EXK $2.46
- GERN $1.17
- 52 Week High
- EXK $5.67
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- EXK 63.02
- GERN 54.80
- Support Level
- EXK $3.50
- GERN $1.40
- Resistance Level
- EXK $3.72
- GERN $1.60
- Average True Range (ATR)
- EXK 0.18
- GERN 0.11
- MACD
- EXK 0.06
- GERN 0.03
- Stochastic Oscillator
- EXK 89.58
- GERN 69.64
About EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.